Sio Gene Therapies Inc. Common Stock
SIOX
SIOX was delisted on the 22nd of March, 2023.
101 hedge funds and large institutions have $1.25B invested in Sio Gene Therapies Inc. Common Stock in 2016 Q4 according to their latest regulatory filings, with 19 funds opening new positions, 36 increasing their positions, 27 reducing their positions, and 12 closing their positions.
102% more call options, than puts
Call options by funds: $13.9M | Put options by funds: $6.88M
58% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 12
33% more repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 27
6% more funds holding
Funds holding: 95 → 101 (+6)
13% less capital invested
Capital invested by funds: $1.43B → $1.25B (-$180M)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital Research Global Investors
Los Angeles,
California
|
+$57.4M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$3.59M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$3.49M |
| 4 |
JHIU
Janus Henderson Investors US
Denver,
Colorado
|
+$3.44M |
| 5 |
Goldman Sachs
New York
|
+$1.79M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$70M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$8.34M |
| 3 |
GTC
Ghost Tree Capital
New York
|
-$5.6M |
| 4 |
Asset Management One
Tokyo,
Japan
|
-$5.12M |
| 5 |
Millennium Management
New York
|
-$3.71M |
SIOX Hedge Fund Activity: Q4 2016 in Review
101 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Sio Gene Therapies Inc. Common Stock (SIOX) for Q4 2016, worth a combined $1.25B — down 13% from $1.43B a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new SIOX positions and 12 closed out — a net gain of 7 holders — while 36 added to existing stakes and 27 trimmed.
The largest buyer was Capital Research Global Investors, opening a new position worth an estimated $57.4M. The largest seller was RA Capital Management, exiting entirely with an estimated $70M sold.
- 101 institutional investors held Sio Gene Therapies Inc. Common Stock (SIOX) as of Q4 2016, up from 95 in Q3 2016.
- Funds reported $1.25B of Sio Gene Therapies Inc. Common Stock stock for Q4 2016, down 13% quarter-over-quarter.
- 19 funds opened new Sio Gene Therapies Inc. Common Stock positions in Q4 2016 and 12 closed out, a net change of +7 holders.
- The largest Sio Gene Therapies Inc. Common Stock buyer in Q4 2016 was Capital Research Global Investors, an estimated $57.4M added.
- The largest Sio Gene Therapies Inc. Common Stock seller in Q4 2016 was RA Capital Management, an estimated $70M sold.
Based on aggregated 13F filings for Q4 2016.